ACE inhibitor fosinopril in the treatment of hypertension: potential benefits
https://doi.org/10.21518/2079-701X-2014-7-26-29
Abstract
Fosinopril with dual clearance can be used in renal failure without dose correction, which may be required in diabetes or elderly patients even with normal creatinine level in blood plasma. Therefore, fosinopril can be indicated as the drug of choice in patients with renal failure and high risk of kidney disease. Fosinopril can be used either as monotherapy or in combination with hydrochlorothiazide, including fixed combinations.
About the Author
AO Konradi
V.A. Almazov Federal Medical Research Centre, Ministry of Health of Russia, St. Petersburg
Russian Federation
Russian Federation
References
1. Mac Mahon NB, Cauman S. Effects of ACE inhibitors, calcium antagonists, and other blob pressure lowering drugs: results of prospectively designed overviews of randomized trials. BPLTCT. Lancet, 2004, 345: 1076-1078.
2. Koch M, Thomas B, Tschope E et al. Survival and predictors of death in dialyzed diabetic patients. Diabetologia, 1993, 10: 1515-1516.
3. Walker WG, Cutler J, Neuwirth R et al. Blood pressure and renal function in the Multiple Factor Intervention Trial (MRFIT).J. Hypertens, 1990, 8 (Suppl. 3) VA. 3
4. Kafettz K. Renal impairment in the elderly: a review. J R Soc Med, 1983, 76: 398-401.
5. Hasslacher C, Ritz E, Wahl P et al. Similar risks of nephropathy in patients with type I and type I diabetes mellitus. Nephrol Dialysis Transpl, 1994, 9: 1097-1102.
6. Biesenbach G, Janco O, Zazgornic J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus Nephrol Dialysis Transpl, 1993, 36: 1071-1078.
7. Deedwania PC. Hypertension and diabetes; new therapeutic options. Arch Intern Med, 200, 160: 1985.
8. Freidman JR, Norman DC, Yoshikawa TT et al. Correlation of estimates renal function parameters versus 24-hour creatinine clearance in ambulatory elderly. J Am Geriatr Soc, 1989, 37: 145-149.
9. Rostand SG, Brown G, Kirk KA et al. Renal insufficiency in treated hypertensive patients. NEng J med, 1989, 320: 684-688.
10. Hall A.S. Ace inhibition and target organ protection 1998; Hoechst Marion Roussel. Chapter 7.
11. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of ACE inhibition on diabetic nephropathy. N Eng J Med, 1993, 329: 1456-1462.
12. Viberti GC, Mogenson CE, Groop LC et al. Effects of captopril on progression of clinical proteinuria in patients with insulin-dependent diabetes mellitus. JAMA, 1994, 271: 275-279.
13. Laffel LMB, McGill B, Gans DG et al. The beneficial effect of ACE with captopril on diabetic nephropathy in patients with type 1 diabetes mellitus. Am J med, 1995, 99: 497-504.
14. Ravid M, Lang R, Rachmani R et al. Long-term renoprotective effect of ACE inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med, 1996, 156: 286-289.
15. Trevisan R, Tiergo A., Effect of low-dose ramipril on microalbuminuria in normotensive or mils hypertensive non-insulin diabetic patients. Am J Hypertension, 1995, 8: 876-883.
16. Lebovitz HE, Weigrmann TB, Cnaan A et al. Renal protective effects of enalapril in hypertensive NISSM: role of baseline albumin-uria. Kidney Int, 45: S150-S155.
17. Penegrer TV, Klag MJ, Feldman HI et al, Projections of hypertension-related renal disease in middle-aged residents of the United States. JAMA, 1993, 269: 1272-1277.
18. Ruilope LM, Alcazar JM, Hernandez E et al. Long-term influence of antihypertensive therapy on microalbuminuria in essential hypertension Kydney Int, 1994, 45: 171-173.
19. Martinez M, Moreno A, Aguirre A et al. Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study. J Hypertension, 2001, 19: 319-326.
20. Debusmann ER, Pujadas JO, Lahn W et al. Influence of renal function on the pharmacokinetics of ramipril. Am J Cardiol, 1987, 59: 70D-78D.
21. White CM. Pharmacologic, pharmakinetic and therapeutic differences among ACE inhibitors. Pharmacotherapy, 1998, 18: 588-598.
22. Veller W. Treatment of Senile hypertension. The fosinopril in old patients study. AJH, 1997, 10: 255S-261S.
23. Diercks GF; Janssen WM; van Boven AJ; Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbu-minuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol, 2000, Sep. 15, 86 (6): 635-8.
24. Costanzi S, Fulignati P, Passalacqua S et al. Nephritic syndrome and ACE inhibitors. Nephrol Dial Transplant, 1992, 7: 706-707.
25. Rodicio JL, Praga M, Alcazar JM. Effetcs of ACE inhibitors on the progression of renal failure and proteinuia in humans. J Hypertens, 1989, 7: 543-549.
26. Cansevoort RT, Sluiter WL, Hemmelder MG et al. Antiproteiuretic effect of blood pressure lowering agents: a metaanalysis of clinical trials. Nephrol Dial Transplant, 1995, 10: 1963-1974.
27. Ruiple MR, Aranda AP, Diez SJ et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens, 2001, 10: 1871-1876.
Review
For citations:
Konradi A. ACE inhibitor fosinopril in the treatment of hypertension: potential benefits. Meditsinskiy sovet = Medical Council. 2014;(7):26-29. (In Russ.) https://doi.org/10.21518/2079-701X-2014-7-26-29
Views:
830
Email this article 